×
ADVERTISEMENT

JUNE 3, 2025

MAD-ID 2025

Barriers to Prescribing Effective Recurrent CDI Therapies


Originally published by our sister publication Infectious Disease Special Edition

By Meaghan Lee Callaghan

Although specific products have been shown to be effective for recurrent Clostridioides difficile infections (CDIs), issues with cost and access have prevented some hospitals from using them, according to a presentation at MAD-ID 2025, in Orlando, Fla.  

Rachel Kenney, PharmD, BCIDP, a pharmacy specialist in antimicrobial stewardship at Henry Ford Hospital, in Detroit, discussed